Here's Why Agios Pharmaceuticals Crashed 23% Today [Globe and Mail, The (Toronto, Canada)]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Globe and Mail, The
Novo's etavopivat outperformed Agios' mitapavit in key sickle cell endpoints, Novo plans to file for FDA approval in late 2026, threatening Agios' market potential. Shares in Agios Pharmaceuticals (NASDAQ: AGIO) slumped by 23% as of 11 a.m. today. As is often the case with small-cap healthcare stocks, the move isn't so much dictated by what the company is doing as by what a much larger company, Novo Nordisk (NYSE: NVO) , reported today. What happened wth Novo Nordisk today In case you are wondering, Novo Nordisk stock barely moved today. It's a performance that reflects the relative importance of healthcare companies' sickle cell treatments to their respective bottom lines. Today's news was that Novo's oral, once-daily, pyruvate kinase-R (PKR) activator, etavopivat, is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, according to Novo's release. Will AI create the world's first trillionaire? Our team just released a report on
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals (AGIO) had its price target lowered by HC Wainwright from $65.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Agios Pharmaceuticals (AGIO) had its price target raised by JPMorgan Chase & Co. from $31.00 to $36.00. They now have a "neutral" rating on the stock.MarketBeat
- Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ETGlobeNewswire
- Agios Pharmaceuticals (AGIO) had its price target raised by The Goldman Sachs Group, Inc. from $28.00 to $32.00. They now have a "neutral" rating on the stock.MarketBeat
- Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & KorsinskyPR Newswire
AGIO
Earnings
- 2/12/26 - Miss
AGIO
Sec Filings
- 4/6/26 - Form 4
- 4/6/26 - Form 4
- 4/6/26 - Form 4
- AGIO's page on the SEC website